Forbes Names Luminex Corporation One of the 25 Fastest-Growing Technology Companies in America
AUSTIN, Texas--([ BUSINESS WIRE ])--Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has been named one of the 25 Fastest-Growing Technology Companies in America by Forbes.
"We are honored to be recognized by Forbes for our strong financial performance, growth and execution," said Patrick J. Balthrop, president and chief executive officer of Luminex Corporation. "Luminex's continued growth reflects the increasing adoption of our multiplexing technology across the life science and diagnostic industries, and the commitment of our customers, strategic partners and employees to positively impact the health, safety and quality of life of people worldwide."
Luminex's multiplexing xMAP® Technology platform allows scientists to conduct multiple, simultaneous tests on a single sample, providing clinicians and researchers with quick, accurate, and cost-effective results. The company continuously seeks to develop and market new, innovative applications for its technology. Today, xMAP Technology can be found in clinics and laboratories around the world in market segments such as life science research, molecular diagnostics, HLA testing, and markets as diverse as biodefense, animal health and agro-biotech.
Companies named to the Forbes 25 Fastest Growing Technology Company list must have revenues of $25 million or more, annualized sales gains of at least 10 percent over the past five years and be profitable over the past 12 months. Forbes also requires a Thomson IBES long-term consensus profit forecast of at least 10 percent, annualized.
More information on Forbes' list of America's 25 Fastest-Growing Tech Companies can be found at [ http://www.forbes.com/2009/01/29/fast-technology-equities-technology_0129_fasttech_land.html ].
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at [ www.luminexcorp.com ].